Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Hypoglycaemia risk is highest in patients also taking sulphonylureas or insulin, those fasting, or those with renal impairment
10.1016/j.jff.2026.107165 3 Alegre-AbarrateguiJ.BrimblecombeK
Written By: Samiksha Jadhav BPharm Reviewed By: Pharmacally Editorial Team Regeneron Pharmaceuticals has reported positive topline results from a Phase 3 clinical trial evaluating olatorepatide, a dual GLP-1/GIP receptor agonist being developed for adults with obesity or overweight
Reinforcement learning in medical image analysis: concepts, applications, challenges, and future directions
US$ 26.14
US$ 24.88
US$ 26.31
US$ 29.41
US$ 23.30
US$ 26.04
US$ 29.23
US$ 24.10
US$ 27.75
US$ 27.54
US$ 22.44
![Gengar (35/83) [XY: Generations] 63](https://cdn.shopify.com/s/files/1/0605/1722/0547/files/7a553b77-f213-49d9-bd5c-b3315461f3a1.png?v=1736283978)
